Home >  News >  Industry >  Pharma News >  India played key role...

India played key role globally in vaccine development, drugs manufacturing during COVID pandemic: WHO Chief Scientist

Two main things that are bringing the countries at the G20 meet here together are digital health initiative, and science & technology, research and development and manufacturing.;

By - Ruchika Sharma
Published On 2023-06-07 10:00 GMT   |   Update On 2024-02-13 17:54 GMT
Advertisement

Hyderabad: India played a key role globally in the development of vaccines and manufacturing of drugs, diagnostics and therapeutics in the three years of the COVID-19 pandemic, WHO Chief Scientist Jeremy Farrar said on Tuesday.

Dr Farrar, who is attending the third G20 Health Working Group meeting here, praised India for the way it has hosted the G20 presidency despite complications and tensions around the world.
Advertisement
"The world's a very complicated place at the moment. It's tense. We all lived through the last three years of a terrific pandemic. India played an absolutely critical role in science and technology, development of vaccines, manufacturing of drugs, diagnostics and therapeutics. It played a key role globally," Farrar said.
Two main things that are bringing the countries at the G20 meet here together are digital health initiative, and science & technology, research & development and manufacturing.
"India has played a key role in ensuring the digital health reaches everyone in the world -- universal coverage and primary care and making sure we live in a more equitable world in future," he said.
"I think the progress we have made here in the last few days is to make sure we have a future with inevitable pandemics where we have more equitable access to countermeasures we need -- drugs, diagnostics and vaccines -- and India along with partners at the G20 can provide that for the world," Farrar said.
The third G20 Health Working Group meeting is being held in Hyderabad from June 4 to 6. It focuses on three priorities in the health track. One of the priorities is health emergency prevention, preparedness and response with a focus on antimicrobial resistance and the One Health framework.
The second is strengthening cooperation in the pharmaceutical sector with a focus on access and availability to safe, effective, quality and affordable medical countermeasures. The third is digital health innovations and solutions to aid universal health coverage and improve healthcare service delivery.
Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Shilpa Pharma Lifesciences Unit-1 successfully completes GMP inspection from Brazilian regulatory authority

Lupin rolls out Nasal spray for rhinorrhea relief in US

Pfizer Told To Conduct Phase IV Trial of Abrocitinib in Indian Adolescents with Atopic Dermatitis

CBI Cracks Down on PCI Chief Montu Patel in College Bribery Scandal

Submit Full Adverse Event Data from Lenvatinib Phase IV Liver Cancer Trial: CDSCO Panel To Eisai Pharma

Over 700 bottles of Codeine Cough Syrup seized, 2 arrested

Massive Rs 1.2 crore Oxytocin seizure in Lucknow, 3 held

High-Alcohol Medicinal Preparations to Come Under Schedule H1: Govt Panel Approves Rule Change